The Study of Jag1-Notch in the Extravasation of Triple Negative Breast Cancer Cells in Metastasis.
Jag1-Notch 在三阴性乳腺癌细胞转移中外渗的研究。
基本信息
- 批准号:10676314
- 负责人:
- 金额:$ 5.27万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-16 至 2025-03-15
- 项目状态:未结题
- 来源:
- 关键词:AdhesionsAdjuvant ChemotherapyAffectBindingBloodBlood VesselsBlood capillariesBreast Cancer CellBreast Cancer PatientBreast cancer metastasisCRISPR/Cas technologyCell AdhesionCell CommunicationCell surfaceCellsCirculationClinicalClustered Regularly Interspaced Short Palindromic RepeatsComplexConsensusDataDiseaseDistantDistant MetastasisDropsEducationElementsEndothelial CellsEndotheliumExposure toExtravasationFellowshipFutureGene ExpressionGene Expression ProfileGenetic Complementation TestGenetic TranscriptionHematogenousICAM1 geneIn VitroInjectionsInvadedKnock-outLeukocytesLigandsLinkLiquid substanceLocalized DiseaseLungLymphaticMediatingMetastatic breast cancerMicrofluidicsModelingMolecular TargetMusNeoplasm MetastasisOncologyOperative Surgical ProceduresOrganOutcomePathway interactionsPatientsPhenotypePhysiciansProteinsResearchResearch ProposalsRoleScientistSeriesSignal TransductionStudentsSurvival RateSystemTailTestingTherapeuticTherapeutic InterventionTissuesTrainingTumor AngiogenesisTumor PromotionTumor-DerivedVascular Endothelial CellVascular EndotheliumVascular SystemVeinsVisualizationWorkaggressive breast cancerbreast cancer diagnosiscancer cellcancer subtypescancer typecandidate identificationclinically actionableeducation planningeffective therapyexpectationimprovedin vivoinsightknock-downmalignant breast neoplasmmigrationmolecular subtypesmortalityneoplastic cellnew therapeutic targetnotch proteinnovelparacrineprogramsshear stressskillstranscriptome sequencingtreatment strategytriple-negative invasive breast carcinomatumortumor growthvascular bed
项目摘要
Project Summary
Triple negative breast cancer (TNBC) makes up to 15-20% of breast cancer diagnoses. While surgery and
adjuvant chemotherapy are effective treatment options for early-stage disease, there are very few therapeutic
options for advanced metastatic TNBC, and the 11% relative five-year survival rate highlights an urgent need to
discover actionable targets. In the hematogenous metastatic cascade, a few aggressive tumor cells are capable
of crossing the endothelial barrier at least twice: when entering systemic circulation (intravasation) and then
again when exiting circulation to colonize distant organs (extravasation). High expression of JAGGED-1 (JAG1),
a Notch ligand, is strongly associated with TNBC metastasis and consequent mortality. Our preliminary work in
static culture suggests that JAG1 enhances TNBC binding to the endothelium and transendothelial migration
(TEM), thereby promoting dissemination of tumor cells through vascular beds. We propose to study two distinct
mechanisms for JAG1 in the metastatic cascade. In Aim 1, we will investigate how tumor JAG1 signals in trans
to the endothelium to prime the vascular barrier for invasion. We will examine extravasation of our recently
generated TNBC CRISPR JAG1 knockout clones and control cells using a microfluidics system that faithfully
models capillary fluid shear forces and permits visualization of multiple critical steps of extravasation in vitro. We
will also test the role of JAG1 in vivo by examining the rate of lung capillary extravasation and pulmonary seeding
following tail vein injection of JAG1 knockout and control TNBC cells. In Aim 2, we will define the tumor cell-
intrinsic transcriptional program regulated by JAG1. Our preliminary RNA sequencing data suggest that novel
JAG1 targets promote cell surface interactions distinct from Notch targets. We will determine the metastatic
importance of key JAG1 targets by restoring expression and testing for TEM phenotypes. In the training plan of
the fellowship, I highlight an integrated scientific, clinical, and educational blueprint to enhance my personal
research and doctoring skills as an aspiring physician-scientist in oncology.
项目概要
三阴性乳腺癌 (TNBC) 占乳腺癌诊断的 15-20%。当手术和
辅助化疗是早期疾病的有效治疗选择,但治疗方法很少
晚期转移性 TNBC 的选择,11% 的相对五年生存率凸显了迫切需要
发现可操作的目标。在血行转移级联中,一些侵袭性肿瘤细胞能够
穿过内皮屏障至少两次:进入体循环(内渗)时,然后
当退出循环以定植远处器官时再次发生(外渗)。 JAGGED-1 (JAG1) 高表达,
Notch 配体,与 TNBC 转移和随后的死亡率密切相关。我们的前期工作
静态培养表明 JAG1 增强 TNBC 与内皮的结合和跨内皮迁移
(TEM),从而促进肿瘤细胞通过血管床传播。我们建议研究两种不同的
JAG1 在转移级联中的机制。在目标 1 中,我们将研究肿瘤 JAG1 如何在反式中发出信号
到内皮细胞,为血管屏障的侵袭做好准备。我们将检查最近的外渗情况
使用微流体系统生成 TNBC CRISPR JAG1 敲除克隆和对照细胞,忠实地
模拟毛细管流体剪切力并允许体外外渗的多个关键步骤的可视化。我们
还将通过检查肺毛细血管外渗率和肺播种率来测试 JAG1 在体内的作用
尾静脉注射 JAG1 敲除细胞和对照 TNBC 细胞后。在目标 2 中,我们将定义肿瘤细胞——
由 JAG1 调节的内在转录程序。我们的初步 RNA 测序数据表明,新的
JAG1 靶标促进细胞表面相互作用,与 Notch 靶标不同。我们将确定转移性
通过恢复表达和测试 TEM 表型来了解关键 JAG1 靶标的重要性。在培训计划中
在奖学金中,我强调了一个综合的科学、临床和教育蓝图,以增强我的个人能力
作为一名有抱负的肿瘤学医师科学家的研究和医生技能。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Benjamin Gordon其他文献
Benjamin Gordon的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Benjamin Gordon', 18)}}的其他基金
The Study of Jag1-Notch in the Extravasation of Triple Negative Breast Cancer Cells in Metastasis.
Jag1-Notch 在三阴性乳腺癌细胞转移中外渗的研究。
- 批准号:
10314566 - 财政年份:2021
- 资助金额:
$ 5.27万 - 项目类别:
The Study of Jag1-Notch in the Extravasation of Triple Negative Breast Cancer Cells in Metastasis.
Jag1-Notch 在三阴性乳腺癌细胞转移中外渗的研究。
- 批准号:
10556318 - 财政年份:2021
- 资助金额:
$ 5.27万 - 项目类别:
相似国自然基金
影响食管癌新辅助放化疗疗效的分子与影像标志物挖掘及其相关性研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
新辅助放化疗驱动的食管鳞癌克隆进化及基因突变对食管鳞癌放化疗敏感性影响的研究
- 批准号:81871975
- 批准年份:2018
- 资助金额:54.0 万元
- 项目类别:面上项目
NONO对前列腺癌脂质代谢影响及指导他汀类药物对前列腺癌的个体化治疗的研究
- 批准号:81601524
- 批准年份:2016
- 资助金额:17.0 万元
- 项目类别:青年科学基金项目
新辅助放化疗对直肠癌区域淋巴结中CD169阳性T细胞的影响和调控机制
- 批准号:81502459
- 批准年份:2015
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
FoxP3介导的胃癌细胞-Treg的交互作用对胃癌术前新辅助放化疗后抗肿瘤免疫应答的影响及机制
- 批准号:81502005
- 批准年份:2015
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
相似海外基金
The Study of Jag1-Notch in the Extravasation of Triple Negative Breast Cancer Cells in Metastasis.
Jag1-Notch 在三阴性乳腺癌细胞转移中外渗的研究。
- 批准号:
10556318 - 财政年份:2021
- 资助金额:
$ 5.27万 - 项目类别:
Rebuilding T cells for Cancer Immunodeficiencies
重建 T 细胞治疗癌症免疫缺陷
- 批准号:
9101552 - 财政年份:2016
- 资助金额:
$ 5.27万 - 项目类别:
Investigating the mechanism of ITGA4/6-mediated chemoprotection of ALL cells
研究 ITGA4/6 介导的 ALL 细胞化学保护机制
- 批准号:
8579820 - 财政年份:2013
- 资助金额:
$ 5.27万 - 项目类别:
Investigating the mechanism of ITGA4/6-mediated chemoprotection of ALL cells
研究 ITGA4/6 介导的 ALL 细胞化学保护机制
- 批准号:
8699167 - 财政年份:2013
- 资助金额:
$ 5.27万 - 项目类别:
Investigating the mechanism of ITGA4/6-mediated chemoprotection of ALL cells
研究 ITGA4/6 介导的 ALL 细胞化学保护机制
- 批准号:
8852571 - 财政年份:2013
- 资助金额:
$ 5.27万 - 项目类别: